Sandip Agarwala is a Managing Director of Longitude Capital focused on investments in biotechnology. He currently serves on the boards of Cydan Development, Endeavor Biomedicines, LEXEO Therapeutics, Opna IO, Talaris Therapeutics, and is involved with Longitude’s investments in Crown Wheel Partners and Inozyme Pharma. Prior to joining Longitude, Mr. Agarwala was at Auven Therapeutics, a life sciences private equity firm, and was a consultant in the healthcare practice at the Boston Consulting Group. Mr. Agarwala’s professional experience also includes roles at Healthcare Royalty Partners, Paul Capital Partners and The Frankel Group, a boutique healthcare consulting firm. Mr. Agarwala holds an M.B.A. in Finance and Health Care Management from the Wharton School of Business at the University of Pennsylvania and a B.S.E. in Systems Engineering from the University of Pennsylvania.